Update on the use of aromatase inhibitors in breast cancer

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2006-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14656566.7.14.1919PMID 17020418
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ferrous sulfate

  2007cited by this paper
• Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition.

  2006cited by this paper
• Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials

  2006cited by this paper
• Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells.

  2005cited by this paper
• Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.

  2005cited by this paper
• The final catalytic step of cytochrome p450 aromatase: a density functional theory study.

  2005cited by this paper
• Aromatase inhibitors in the treatment of breast cancer.

  2005cited by this paper
• A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

  2005cited by this paper
• Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer.

  2005cited by this paper
• Aromatase inhibitors — mechanisms of steroidal inhibitors

  2004cited by this paper
• A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

  2004cited by this paper
• Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients

  2004cited by this paper
• The role of COX-2 inhibition in breast cancer treatment and prevention.

  2004cited by this paper
• Arimidex®: A potent and selective fourth-generation aromatase inhibitor

  2004cited by this paper
• Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands

  2004cited by this paper
• First generation aromatase inhibitors — aminoglutethimide and testololactone

  2004cited by this paper
• A new irreversible aromatase inhibitor, 6-methylenandrosta-1,4-diene-3,17-dione (FCE 24304): antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors

  2004cited by this paper
• Organization of the human aromatase p450 (CYP19) gene.

  2004cited by this paper
• A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer*

  2004cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.

  2003cited by this paper
• Breast cancer prevention--clinical trials strategies involving aromatase inhibitors.

  2003cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer

  2003cited by this paper
• Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

  2003cited by this paper
• Applicability of the Intratumor Aromatase Preclinical Model to Predict Clinical Trial Results With Endocrine Therapy

  2003cited by this paper
• Validation of new aromatase monoclonal antibodies for immunohistochemistry: progress report.

  2003cited by this paper
• Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes.

  2003cited by this paper
• Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism.

  2002cited by this paper
• Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.

  2002cited by this paper
• American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

  2002cited by this paper
• Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.

  2002cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

  2002cited by this paper
• Aromatase--a brief overview.

  2002cited by this paper
• Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.

  2001cited by this paper
• Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.

  2001cited by this paper
• Nonsteroidal and steroidal aromatase inhibitors in breast cancer.

  2001cited by this paper
• Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.

  2001cited by this paper
• Aromatase inhibitors in the treatment and prevention of breast cancer.

  2001cited by this paper
• Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention.

  2001cited by this paper
• Gemcitabine plus cisplatin in breast cancer.

  2001cited by this paper
• Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined Analysis

  2001cited by this paper
• Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors.

  2001cited by this paper
• Anastrozole is superior to tamoxifen as first‐line therapy in hormone receptor positive advanced breast carcinoma

  2001cited by this paper
• Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.

  2001cited by this paper
• Human aromatase in high yield and purity by perfusion chromatography and its characterization by difference spectroscopy and mass spectrometry.

  2001cited by this paper
• Aromatase and COX-2 expression in human breast cancers.

  2001cited by this paper
• Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.

  2000cited by this paper
• Pharmacology and clinical experience with exemestane

  2000cited by this paper
• Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.

  2000cited by this paper
• Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.

  2000cited by this paper
• Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer.

  1999cited by this paper
• Aromatase and its inhibitors.

  1999cited by this paper
• Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens.

  1999cited by this paper
• Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients.

  1999cited by this paper
• Effects of matrix components on aromatase activity in breast stromal cells in culture.

  1999cited by this paper
• Use of aromatase inhibitors in breast carcinoma.

  1999cited by this paper
• Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.

  1998cited by this paper
• In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.

  1998cited by this paper
• A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.

  1997cited by this paper
• Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.

  1997cited by this paper
• Aromatase inhibitors and breast cancer.

  1997cited by this paper
• A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma

  1997cited by this paper
• Transcriptional regulation of CYP19 gene (aromatase) expression in adipose stromal cells in primary culture.

  1997cited by this paper
• The minimal effective exemestane dose for endocrine activity in advanced breast cancer.

  1997cited by this paper
• Binding characteristics of aromatase inhibitors and phytoestrogens to human aromatase.

  1997cited by this paper
• Regulation of aromatase activity within the breast.

  1997cited by this paper
• Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

  1996cited by this paper
• Nonsteroidal antiinflammatory drugs and breast cancer.

  1996cited by this paper
• Aromatase inhibitors and breast cancer.

  1996cited by this paper
• A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

  1996cited by this paper
• Regulation of arachidonic acid metabolism, aromatase activity and growth in human breast cancer cells by interleukin‐1β and phorbol ester: Dissociation of a mediatory role for prostaglandin E2 in the autocrine control of cell function

  1996influential reference
• Formestane

  1996cited by this paper
• Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.

  1996cited by this paper
• Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene.

  1996cited by this paper
• In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.

  1995cited by this paper
• Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers: toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone.

  1994cited by this paper
• Modern techniques in radiological imaging related to oncology.

  1994cited by this paper
• Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats.

  1994cited by this paper
• Aromatase inhibition: basic concepts, and the pharmacodynamics of formestane.

  1994cited by this paper
• Aromatase inhibitors in the treatment of breast cancer.

  1994cited by this paper
• Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis.

  1994cited by this paper
• Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors.

  1993cited by this paper
• A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription.

  1993cited by this paper
• Tissue-specific promoters regulate aromatase cytochrome P450 expression.

  1993cited by this paper
• Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats.

  1993cited by this paper
• Control of aromatase activity in breast cancer cells: the role of cytokines and growth factors.

  1993cited by this paper
• Control of aromatase in breast cancer cells and its importance for tumor growth.

  1993cited by this paper
• A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription [published erratum appears in J Clin Endocrinol Metab 1994 Feb;78(2):494]

  1993cited by this paper
• Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.

  1992cited by this paper
• Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors.

  1992cited by this paper
• Novel Irreversible Aromatase Inhibitors

  1990cited by this paper
• Mechanism and inhibition of cytochrome P-450 aromatase.

  1990cited by this paper
• Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor.

  1990cited by this paper
• Biochemical and molecular aspects of aromatase.

  1990cited by this paper
• in situ oestrone synthesis in normal breast and breast tumour tissues: Effect of treatment with 4‐hydroxyandrostenedione

  1989cited by this paper
• 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor.

  1988cited by this paper
• The importance of local synthesis of estrogen within the breast.

  1987cited by this paper
• Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies.

  1987cited by this paper
• Purification and characterization of human placental aromatase cytochrome P-450.

  1987cited by this paper
• 4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer.

  1987cited by this paper
• Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo. Identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat.

  1986cited by this paper

• 1,2,5-Thiadiazocan-7-one 1,1-dioxides — a novel charted region in the chemical space of 8-membered azasultams

  2026cites this paper
• A Narrative Review on Breast Cancer Treatment Supported by Focused and Systemic Phytotherapy

  2025cites this paper
• Ferrozoles: Ferrocenyl derivatives of letrozole with dual effects as potent aromatase inhibitors and cytostatic agents

  2023cites this paper
• Structures and Functions of Human Placental Aromatase and Steroid Sulfatase, Two Key Enzymes in Estrogen Biosynthesis.

  2023cites this paper
• Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence

  2022cites this paper
• Aromatase inhibitors in Breast Cancer

  2021cites this paper
• Multifaceted 3D-QSAR analysis for the identification of pharmacophoric features of biphenyl analogues as aromatase inhibitors

  2021cites this paper
• Protective Effects and Possible Mechanisms of Actions of Bushen Cuyun Recipe on Diminished Ovarian Reserve Induced by Cyclophosphamide in Rats

  2020cites this paper
• Development of in vitro and in vivo models to underpin advances in human radiotherapy

  2020influential citation
• Design and pharmacophoric identification of flavonoid scaffold‐based aromatase inhibitors

  2020cites this paper
• Effective anti-aromatase therapy to battle against estrogen-mediated breast cancer: Comparative SAR/QSAR assessment on steroidal aromatase inhibitors.

  2020cites this paper
• B12Y12 (Y: N, P) fullerene-like cages for exemestane-delivery; molecular modeling investigation

  2020cites this paper
• Recent Studies on Aromatase and Sulfatase Involved in Breast Cancer and their Inhibitors

  2020cites this paper
• Naturally-Occurring Canine Mammary Tumors as a Translational Model for Human Breast Cancer

  2020cites this paper
• Insights into how phosphorylation of estrogen receptor at serine 305 modulates tamoxifen activity in breast cancer.

  2019cites this paper
• UF-LC-DAD-MSn for discovering enzyme inhibitors for nutraceuticals and functional foods

  2019cites this paper
• Synthesis, Biological Evaluation and Docking Studies of 13-Epimeric 10-fluoro- and 10-Chloroestra-1,4-dien-3-ones as Potential Aromatase Inhibitors

  2019cites this paper
• Structure Guided Molecular Docking Assisted Alignment Dependent 3DQSAR Study on Steroidal Aromatase Inhibitors (SAIs) as Anti-breast Cancer Agents

  2019cites this paper
• Aromatase and Aromatase Inhibitors in Breast Cancer Treatment

  2018cites this paper
• Endocrine Resistance and Breast Cancer Stem Cells: The Inflammatory Connection that Could Lead to New and Improved Therapy Outcomes

  2017cites this paper
• Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.

  2016cites this paper
• Androgen-metabolizing enzymes: A structural perspective.

  2016cites this paper
• Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer.

  2015cites this paper
• Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer.

  2015cites this paper
• Synthesis, Biological Evaluation and Molecular Docking Studies of Ferrocene Derivatives Coupling with N-heterocyclic on Human Breast Cancer

  2015cites this paper
• Structure, Function and Inhibition of Aromatase

  2015cites this paper
• Mechanism of inhibition of estrogen biosynthesis by azole fungicides.

  2014cites this paper
• Eicosanoids and Adipokines in Breast Cancer: From Molecular Mechanisms to Clinical Considerations

  2013cites this paper
• Novel aromatase inhibitors by structure-guided design.

  2012cites this paper
• Estrogen Receptor-beta Mediates the Protective Effects of Aromatase Induction in the MMTV-Her-2/neu x Aromatase Double Transgenic Mice

  2012cites this paper
• Characterizing the Expression of Cytochrome P450s in Breast Cancer Cells

  2012influential citation
• Pharmacogenetics of anti-estrogen treatment of breast cancer.

  2012cites this paper
• The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer.

  2012cites this paper
• Higher order organization of human placental aromatase.

  2011cites this paper
• Estrogen sulfotransferase (sult1e1) expression and function in mcf10a-series breast epithelial cells: role as a modifier of breast carcinogenesis and regulation by proliferation state

  2011cites this paper
• Drug development for cancer chemoprevention: focus on molecular targets.

  2010cites this paper
• Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression

  2010cites this paper
• Neoadjuvant endocrine therapy in the treatment of early-stage breast cancer

  2010cites this paper
• Vitamin D and breast cancer: inhibition of estrogen synthesis and signaling.

  2010cites this paper
• X-ray structure of human aromatase reveals an androgen-specific active site.

  2010influential citation
• Characterization of Aromatase Binding Agents from the Dichloromethane Extract of Corydalis yanhusuo Using Ultrafiltration and Liquid Chromatography Tandem Mass Spectrometry

  2010cites this paper
• Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.

  2009cites this paper
• Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy.

  2009cites this paper
• HtrA serine proteases as potential therapeutic targets in cancer.

  2009cites this paper
• Isolation and Characterization of Aromatase Inhibitors from Brassaiopsis glomerulata (Araliaceae).

  2009cites this paper
• Is norepinephrine an etiological factor in some types of cancer?

  2009cites this paper
• Aromatase inhibitors: past, present and future in breast cancer therapy

  2008cites this paper
• Molecular mechanisms of aromatase inhibition by new A, D-ring modified steroids

  2008cites this paper
• Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis

  2008cites this paper
• A 3D QSAR Model of 17β‐HSD1 Inhibitors Based on a Thieno[2,3‐d]pyrimidin‐4(3H)‐one Core Applying Molecular Dynamics Simulations and Ligand–Protein Docking

  2008cites this paper
• Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.

  2008cites this paper
• Natural products as aromatase inhibitors.

  2008cites this paper
• Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

  2008cites this paper
• Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity.

  2008cites this paper
• Hormonal therapy for advanced breast cancer.

  2007cites this paper
• SUMO and estrogen receptors in breast cancer

  2007cites this paper
• Cytochromes P450 and drug discovery.

  2007cites this paper
• Pathways to tamoxifen resistance.

  2007cites this paper
• Synthesis, Reactivity and Biological Activity of 17β-HSD1 Inhibitors Based on a Thieno[2,3-d]pryrimidin-4(3H)-one Core

  2007cites this paper
• Cancer therapy disparity: unequal access to breast cancer therapeutics and drug funding in Canada

  2007cites this paper
• ERR Gamma: Does an Orphan Nuclear Receptor Link Steroid Hormone Biogenesis to Endocrine Resistance?

  2007cites this paper